PFE 001
Alternative Names: PFE-001Latest Information Update: 28 Jul 2024
At a glance
- Originator Pfizer
- Class Antianaemics; Small molecules
- Mechanism of Action Abnormal haemoglobin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sickle cell anaemia
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA
- 11 Jun 2020 Preclinical trials in Sickle cell anaemia in USA (unspecified route)
- 11 Jun 2020 Pharmacodynamic data from preclinical trial in Sickle cell anaemia presented at the European Haematology Association (EHA-2020)